Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Discovery of a Potent PARP1 Inhibitor Senaparib.

Molecular cancer therapeutics - 2 Jan 2025

Cai Sui X, Ma Ning, Wang Xiaozhu, Guo Mingchuan, Jiang Yangzhen, Tian Ye E

Abstract excerpt

PARP1 is a critical enzyme involved in DNA damage repair. It belongs to a superfamily of proteins and catalyzes poly(ADP-ribosyl)ation (PARylation). PARP1 inhibitors are effective to treat tumors that have homologous recombination deficiency such as those with BRCA1/2 mutations. The PARP1 inhibitors that have been approved by FDA inhibit both PARP1 and PARP2. PARP2 has also been suggested to play a similar...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Discovery
Share to Drug Synergism
Share to Phthalazines

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Piperazines

Share to Poly (ADP-Ribose) Polymerase-1

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Quinazolines

Share to Temozolomide

Source

Identifiers

PMID: 38920409
DOI: 10.1158/1535-7163.MCT-23-0625

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Discovery of a Potent PARP1 Inhibitor Senaparib.PMID 38920409Read ↗

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancersSemantic proximity Read ↗

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancerSemantic proximity Read ↗

Dual-Target Inhibitors Based on PARP1: New Trend in the Development of Anticancer ResearchSemantic proximity Read ↗

Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase InhibitorsSemantic proximity Read ↗

Structural Implications for Selective Targeting of PARPsSemantic proximity Read ↗

PARP inhibitors: its role in treatment of cancer.Semantic proximity Read ↗

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA MutationsSemantic proximity Read ↗

The recent advance and prospect of poly(ADP‐ribose) polymerase inhibitors for the treatment of cancerSemantic proximity Read ↗

[Research progresses of the PARP inhibitors for the treatment of cancer].Semantic proximity Read ↗

Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)Semantic proximity Read ↗

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic DrugsSemantic proximity Read ↗

[PARP inhibitors--theoretical basis and clinical application].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.